Best response observed among the 51 eligible patients receiving VAC plus valproic acid in refractory/relapsing small cell lung cancer
| Type of response | Subjects n |
| Complete response | 0 |
| Partial response | 10 |
| No change | 5 |
| Progression | 28 |
| Early death due to cancer | 2 |
| Early death due to toxicity | 1 |
| High toxicity | 2 |
| Not evaluable | 3 |
VAC: doxorubicin, vindesine and cyclophosphamide.